Company profile: G1 Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation anticancer therapies, including trilaciclib, a transient intravenous CDK4/6 inhibitor administered before chemotherapy to protect bone marrow and enhance immune function; lerociclib, an oral CDK4/6 inhibitor for use with other therapies; and rintodestrant (G1T48), an oral SERD for estrogen receptor–positive breast cancer.
Products and services
- Lerociclib: Oral CDK4/6 inhibitor being developed for use in combination with other therapies for the treatment of certain cancers
- Rintodestrant (G1T48): Oral selective estrogen receptor degrader being developed for the treatment of estrogen receptor‑positive breast cancer
- Trilaciclib: Intravenous CDK4/6 inhibitor administered transiently before chemotherapy to protect bone marrow and enhance immune function, being evaluated across multiple cancer types and regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to G1 Therapeutics
Kuur Therapeutics
HQ: United Kingdom
Website
- Description: Provider of off-the-shelf engineered CAR-NKT cell therapies, combining the natural biology of natural killer T cells with innovative CAR constructs for cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kuur Therapeutics company profile →
Gradalis
HQ: United States
Website
- Description: Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gradalis company profile →
Lumicell
HQ: United States
Website
- Description: Provider of image-guided cancer surgery solutions, including the Lumicell Direct Visualization System (DVS), a fluorescence-guided imaging system that detects residual cancerous tissue in real time during lumpectomy, and LUMISIGHT (pegulicianine), an optical imaging agent used with DVS to highlight cancerous tissue during lumpectomy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumicell company profile →
Amphista Therapeutics
HQ: United Kingdom
Website
- Description: Provider of next-generation targeted protein degradation therapies and the Eclipsys drug development platform, harnessing the body's natural processes to selectively remove disease-causing proteins. Solutions address a wide range of diseases, including oncology and CNS disorders, and are designed to overcome limitations of first-generation TPD with broad applicability and improved drug properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amphista Therapeutics company profile →
ArQule
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of cancer therapeutics, employing its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs, including ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArQule company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for G1 Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to G1 Therapeutics
2.2 - Growth funds investing in similar companies to G1 Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for G1 Therapeutics
4.2 - Public trading comparable groups for G1 Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →